KMT2A and leukemia: In leukemia, particularly mixed-lineage leukemia rearrangements (MLL-r), LAMP5 is a direct target of the oncogenic MLL fusion protein, and its reduction significantly inhibits leukemia cell growth, highlighting its potential as a therapeutic target (45).